Trials mixed with lifestyle programs

The weight-loss drugs people know by brand names like Wegovy and Zepbound were not tested as “take the shot and do nothing else” treatments. In the biggest obesity trials, participants got the drug plus a structured plan for fewer calories, more movement, and regular coaching. (nejm.org) (pi.lilly.com) These medicines work by making people feel fuller, eat less, and digest food more slowly. That can lower body weight, but it does not teach someone how to shop, cook, sleep, or build muscle any more than a cast teaches someone how to walk after a broken leg. (accessdata.fda.gov 1) (accessdata.fda.gov 2) In the 68-week STEP 1 trial for semaglutide, the drug in Wegovy, 1,961 adults were assigned to semaglutide or placebo, and both groups also got lifestyle intervention. The trial included a roughly 500-calorie daily deficit, at least 150 minutes a week of physical activity, and counseling sessions spread across the study. (nejm.org) (novomedlink.com) In the 72-week SURMOUNT-1 trial for tirzepatide, the drug in Zepbound, 2,539 adults were randomized to one of three doses or placebo. They also started a reduced-calorie diet, got physical-activity counseling, and received behavior-change support throughout the trial. (pi.lilly.com) (clinicaltrials.gov) That detail changes how to read the headline numbers. The often-cited average loss of about 14.9% of body weight with semaglutide in STEP 1 and up to 20.9% with the 15-milligram tirzepatide dose in SURMOUNT-1 came from drug-plus-program studies, not drug-only tests. (nejm.org 1) (nejm.org 2) The labels approved by the Food and Drug Administration still reflect that design. Wegovy and Zepbound are indicated in combination with a reduced-calorie diet and increased physical activity, which is regulatory language for “this is supposed to be used with lifestyle change.” (accessdata.fda.gov 1) (accessdata.fda.gov 2) Doctors keep stressing exercise for another reason: fast weight loss can reduce lean mass, not just fat mass. A 2025 comment in Nature Reviews Endocrinology warned that losing skeletal muscle during treatment can weaken metabolic and physical benefits if patients do not protect muscle on purpose. (nature.com) That is why strength training keeps showing up in expert advice. Mass General Brigham researchers said lasting success with glucagon-like peptide-1 drugs requires individualized nutrition plus physical activity, including resistance training and aerobic exercise. (massgeneralbrigham.org) The evidence is starting to line up behind that approach. A 2025 meta-analysis in Lancet eClinicalMedicine found that lifestyle modification combined with glucagon-like peptide-1 receptor agonists helped reduce body weight and improve cardiometabolic markers in adults with overweight or obesity. (thelancet.com) So when people hear that these drugs “work,” the fine print is that the landmark trials built in diet coaching, exercise targets, and behavior support from day one. The medicine was tested as an add-on engine, not as the whole car. (nejm.org) (pi.lilly.com)